Mucins as Precision Biomarkers in Glioma
Author Information
Author(s): Erickson Anna, Jackson Luke R., Camphausen Kevin, Krauze Andra V.
Primary Institution: Radiation Oncology Branch, National Cancer Institute, National Institutes of Health
Hypothesis
Mucins may serve as non-invasive precision biomarkers for glioma detection and monitoring.
Conclusion
Mucins show promise as biomarkers for glioma, with potential for non-invasive measurement in serum and plasma.
Supporting Evidence
- Mucins are increasingly studied in cancer for their role in disease detection and monitoring.
- CA125, a mucin, is already used as a biomarker in ovarian cancer.
- Mucins have shown differential expression in glioma cells related to tumor detection and patient outcomes.
- Evidence supports the potential of mucins as non-invasive biomarkers in glioma.
Takeaway
Mucins are special proteins that can help doctors find and track brain tumors without needing surgery.
Methodology
The review compiles existing research on mucins as biomarkers in glioma, focusing on their biological roles and measurement methods.
Limitations
The study highlights the need for further validation of mucin measurements in various biospecimens and the challenges in distinguishing tumor signals from normal physiology.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website